This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignees: National Institute of Health and Medical Research, Assistance Publique - Hopitaux De Paris (Aphp), Assistance Publique-Hopitaux De Paris. Active years: 2018-2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 1,853 
1 out of 78 
1 out of 331 
Years Active: 2018-2021
Title: Inventor Spotlight: Jean-Ehrland Ricci
Introduction
Jean-Ehrland Ricci, an accomplished inventor based in Nice, France, is known for his significant contributions to the field of medical research, particularly in lymphoma treatment. With two patents to his name, Ricci's innovations are poised to enhance the understanding and management of lymphatic cancers.
Latest Patents
Ricci's latest patents revolve around groundbreaking methods for determining the metabolic status of lymphomas. His first patent offers an in vitro method that assesses the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in lymphoma cells. This unique approach reveals that low levels of GAPDH expression indicate an oxidative phosphorylation (OXPHOS) status. Additionally, the patent includes a method that predicts how responsive a patient with lymphoma will be to treatments using metabolic inhibitors. By evaluating the same GAPDH expression levels in patient samples, this method provides valuable insights into potential treatment responses.
The second patent focuses on predicting patient responsiveness to anti-CD20 antibody treatments. This innovative method involves measuring GAPDH expression levels in B cells from patients. The results serve as a critical indicator of treatment efficacy, enabling personalized approaches in lymphoma therapy.
Career Highlights
Throughout his career, Jean-Ehrland Ricci has been associated with renowned institutions such as the Institut National de la Santé et de la Recherche Médicale and Assistance Publique—Hôpitaux de Paris. His work has emphasized the intersection of clinical research and innovative methodologies, contributing significantly to advancements in cancer treatment.
Collaborations
Ricci has collaborated with notable colleagues such as Johanna Chiche and Catherine Thieblemont. These partnerships have enhanced the research landscape, fostering shared expertise and innovation in their respective fields.
Conclusion
Jean-Ehrland Ricci stands as a pivotal figure in the realm of lymphoma research and treatment. With his two patents, he highlights the importance of understanding metabolic pathways in cancer therapy, paving the way for novel treatment strategies. His work not only reflects his dedication to innovation but also offers hope for improved outcomes for patients battling lymphoma.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile